TrialFrontiers in nutrition2026

Efficacy of 42-month oral administration of glucoraphanin in preventing cognitive decline in individuals at elevated risk of dementia, including those with mild cognitive impairment: a randomized, double-blind, placebo-controlled pilot study.

Sunao Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.